Life Sciences

Haynes and Boone’s Life Sciences Practice Group has robust experience in medical and surgical devices, drug delivery, biotechnology and biosimilar arts, Food and Drug Administration law and regulations, and intellectual property. We represent a wide array of emerging growth, middle stage and Fortune 100 companies in the biotechnology, consumer medical products and medical technology industries, and have a knowledge base and skillset that is particularly helpful to our clients in this field. Our practitioners represent clients in technology areas, such as:

  • Drug delivery devices including implants, transdermal patches, and injectable devices; drug modeling and prediction
  • Polymer and coatings chemistry, including modified release, immediate release, and disintegrating formulations, biodegradable polymers, enteric coatings, bioresorbable polymers, expanded porphyrin and pyrrole macrocycles, and chemical processes
  • Genetic engineering, transgenic organisms, genomics, gene therapy, proteomics, plant molecular biology, transgenic plants, disease resistance; microbiology, immunology including vaccine and antibody technology, and endocrinology
  • Medical equipment, imaging methods, photodynamic therapy, cardiovascular devices, ophthalmologic diagnostics and treatment, spinal fixation implants and associated surgical methods, general orthopedic implants and total joint replacements, stents, catheters, and a variety of other medical and dental prosthetic devices with related surgical methods

Selected Client Representations

Licensing and Agreements

  • Represent Obagi Medical Products in distribution agreements and license and development agreements.
  • Represented a major medical device company in connection with in-licensing new device technology.

Technology Acquisition, Divestiture, and Investment

  • Represented Strides Arcolab Limited in the U.S. component of the divestiture to Mylan Inc. of its Agila Specialties generic injectables manufacturing business for $1.6 billion cash with up to an additional $250 million upon certain contingencies.
  • Represented KMG-Bernuth, Inc., a subsidiary of KMG Chemicals, Inc., in its $10.5 million sale of its animal health business.
  • Represented RxElite in its acquisition of the Finetech API synthesis and fine chemicals business.
  • Represented a major biotechnology company in connection with the spin-out of major development program to VC-backed venture.
  • Representation of investor in medical device technology startup where we conducted IP diligence of the patent and trademark rights of a complicated corporate family, requiring renegotiation of existing license and consulting agreements between existing corporate entities to protect our client.
  • Confidential representation of many biotechnology companies in connection with all aspects of technology acquisition and commercialization including joint development agreements, acquisition and licensing of technology and co-promotion agreements.

Intellectual Property

Biotechnology | Haynes and Boone, LLP

What to Know About Post-Grant Review and the Biotech Industry

The AIA made several significant changes to United States patent law, including the establishment of post-grant proceedings before the Patent Trials and Appeals Board (PTAB) where patents have the potential of being invalidated in a much more efficient and expedient manner. In the five years since the AIA was enacted, two types of post-grant proceedings, Inter Partes Review (IPR) and Post-Grant Review (PGR), have become increasingly popular tools for biotechnology companies to resolve patent disputes.

Email Disclaimer